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Purpose: The aim of this study was to review the experiences of direct involvement in patient 
survivorship for treatment and research.
Methods: This is a narrative-focused review of the following two recent experiences of patient 
involvement: the Chordoma Foundation and the Triple Negative Breast Cancer Foundation.
Results: These two examples represent concrete experiences that patients have built to favor a 
real involvement in the care and treatment of tumors. These experiences are profoundly modi-
fying how cancer research is conducted and draw attention to the psychosocial dimensions of 
health care.
Conclusion: These examples represent the new scenario in which modern medicine faces 
completely new challenges, copes with new needs, and cooperates with new health care 
professionals.
Implications: Involving patients in a new perspective raises practical and ethical challenges 
for organizations to work together, for health providers to be professionally skilled and for the 
government to promote safeguarding policies.
Keywords: patient empowerment, patients’ association, empowerment, skills, codesign 
 techniques, cancer
Introduction
Over the past 2 decades, the nature of cancer patients and their needs have changed 
significantly.1 Progress in technology and medical sciences, such as the human genome, 
screening techniques, and surgical procedures, has given patients a choice in terms of 
the treatment and care of different types of tumors.2 However, this progress has also 
given rise to a different kind of a cancer patient, one who has increasingly complex 
needs and depends on a high level of technology for his/her survival.3 Nevertheless, 
modern medicine still sustains a strong biomedical approach, missing the “social nature 
of cancer”, or in other words, the social capital, characterized by both the patient’s 
physical and human components.4 The need to consider the patients’ knowledge, 
experiences, and needs is not a mere ethical position. It also has clinical consequences. 
As Sox et al5 posit, health care professionals work most of the time under uncertain 
conditions, where information is limited and ambiguous and the consequences of 
treatment choice are estimated on a probability-based reasoning.6,7 In addition, utili-
ties and values are affected by subjective past experiences, beliefs, and interpersonal 
contexts. From this perspective, important information is locked inside the patient and 
hidden to the professional’s eyes.
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This uncertainty is particularly evident in (but not limited 
to) rare diseases (not only in oncological setting),8–10 where not 
enough clinical evidence is available. In such cases, caring for 
patients must be expanded to include a further, and in a certain 
way, new and challenging concept: working with patients.
In the following section, some significant examples are 
reported where the direct involvement of patients in clinical 
studies and dissemination has been relevant. This article does 
not represent a systematic review as the available examples 
are limited and not structured in every country. This is more 
a narrative-focused review of the main experiences regarding 
collaboration between patients and clinical investigators at 
an international level.
Patients as special collaborators
The example of Josh Sommer, executive director of a research 
organization called the Chordoma Foundation,11 completely 
embodies this approach. Diagnosed with a chordoma, a rare 
bone cancer for which there was a low cure rate, a 7-year 
life-expectancy, very little research, and no approved drugs, 
Sommer believed that the patient can have the power to 
make a difference in research for the cure of chordoma and 
other fatal diseases. Thanks to technology, he rounded up 
patients with the same cancer and all researchers working 
on it, optimizing the resources earlier scattered around the 
world, increasing awareness of the problem, and breaking 
down barriers to progress.
In this perspective, as shown by Stacchiotti et al,12 patients 
are not only passive care receivers but also special collabo-
rators who can proactively help clinicians and researchers 
reduce the aforementioned uncertainty. Important research 
has been conducted on discovering chordoma therapies, for 
example, the utility of some enzymes in the mechanism of 
this tumor.13 Clinical practice guidelines were also drawn up 
in collaboration with the Chordoma Foundation with patients 
playing an active role and were published in an international 
peer-reviewed scientific journal.
Similarly, the Triple Negative Breast Cancer (TNBC) 
Foundation organized a meeting of investigators and advo-
cates to assess the state of current clinical and translational 
research on triple-negative breast cancer and published 
the main recommendations regarding future prospects for 
research into this breast cancer subtype.14
These examples are significant and they propose a new 
methodology for conducting research and publishing data. 
However, these examples are not yet consolidated. Future 
research should implement the gap that exists between tra-
ditional research and the new way of conducting studies with 
the active involvement of patients.
The first step entails empowering the patients by providing 
high-quality up-to-date information. The second involves 
brokering collaborations with patients by taking advantage 
of their skills, knowledge, and desire to exert control on their 
health condition.
In present society, however, the shift from a paternalistic 
approach where the patient is a passive receiver of treatment 
to a patient-centered paradigm in which the patient is an 
active participant is still a slow process. The utility of the 
patient’s perspective as a reflection of his/her personal values, 
expectations, and needs15 is still far from being an integral part 
of modern culture. Take for example the plethora of studies 
on physician–patient communication; it is well-known that 
the most effective communication paradigm is the one that 
reduces the knowledge and influences the asymmetry between 
physicians and patients (ie, only the doctor knows everything) 
and that the medical discussion has to be collaborative, ie, 
the doctor gives a frame to clarify the clinical picture and 
following decisions and the patient states information on his/
her health status, preferences, and previous knowledge about 
the cancer and its treatments.15 In this way, all the relevant 
treatment possibilities are shown, and these possibilities are 
discussed by both the physician and the patient within the 
medical consultation.16 Such a paradigm is effective because 
it allows the physician to generate the shared knowledge 
indispensable for establishing the patient’s involvement and 
for effectively bringing about a shared decision practice.17 
Notwithstanding, this does not happen as frequently as 
patients would like. There still exists a constant gap between 
what patients want and what they get with respect to 
engagement in health care, whereas between 70% and 80% 
of patients strongly want their physician to take into account 
their desires and hopes and values and to engage them in the 
decision process, and less than half report that this is what 
happens in reality.18 In addition, in a worldwide survey on 
cancer patients,19 most of the surveyed patients desired more 
knowledge and involvement concerning treatment and care for 
cancer; for example, ~40% of patients considered that patient 
participation in decision making in cancer is inadequate; in the 
European countries included, the percentage of dissatisfaction 
was ~25% in some countries, such as Italy, and somewhat 
higher (58%) in some countries, such as Germany. In a 
number of countries, it was considered that there is inadequate 
knowledge available to patients about the nature of specific 
types of tumors. On this point, European opinions ranged from 
a low of 31% in Italy to 54% in France who judged that not 
enough knowledge is accessible. In relation to the decision-
making process, the study identified a considerable majority of 
patients (75% in France and Germany, 73% in Italy, and 72% 
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in the UK) who evaluate as extremely important the fact that 
patients and their families should be the leaders in decision 
making about treatment options and timing.
Moreover, several studies focusing on the assessment of 
the most common conceptualizations about cancer found that 
most people know very little about it.20 To be in a position to 
reason and actually take decisions about their medical care, 
patients need to be given by their physician a correct “set of 
knowledge” about their illness. A systematic review of 86 
clinical trials21 found that offering patients clear and evident 
information leads to 1) an enhanced level of knowledge of 
treatment options and medical guidelines, 2) more precise 
probabilities of benefits and risks, 3) being able to evaluate 
a number of choices more compatible with own health status 
and in line with their system of values, and 4) stable patient 
satisfaction. Patients with capacities in information seeking 
are those who better comprehend what is communicated, can 
better evaluate the appropriateness of their condition and are 
able to choose medical treatment in a more appropriate way.
A clear understanding of their actual health situation 
is important to patient involvement, and a more thorough 
understanding of medical knowledge in the general 
population is essential to improving health, particularly that of 
underprivileged populations. Poor health literacy is a political 
challenge, which should be greatly taken into account and 
addressed by health care operators and decision makers22 and 
warrants a higher profile in the political agenda. In some cases, 
private organizations attempt to fill the gap. A good example 
is the TNBC.23 This foundation was established in 2006 in 
honor of Nancy Block-Zenna, a young patient who died from 
triple-negative breast cancer (one of the most aggressive 
forms of breast cancer, which is presented in ~15%–20% of 
breast cancer population). In response to Nancy’s prognosis, 
her close friends founded the TNBC Foundation to promote 
knowledge and support research in this field. One of the 
Foundation’s goals was to ignite interest in the study of TNBC 
among researchers, physicians, and educators. Today, the 
world is very different TNBC wise than when Nancy was 
diagnosed. Women with TNBC are no longer the wallflowers 
at the breast cancer prom. And all over the world, researchers 
are focusing on target therapies for this subtype of breast 
cancer. This is the result of an increased public awareness, 
and undoubtedly, the TNBC Foundation has played a role in it.
Conclusion and implications
Patient involvement has been formulated in a plethora of docu-
ments and guidelines from various international  bodies.24–27 
However, laws and declarations in and of themselves 
 automatically do not make patient involvement in practice, 
nor do they automatically frame health systems in a patient-
centered perspective. Involving patients in a new perspec-
tive raises practical and ethical challenges for organizations 
to work together, for health providers to be professionally 
skilled, and for the government to promote protecting poli-
cies.28 In health care, the term “co-design” refers to patients 
and carers working in partnership with health providers to 
improve clinical research, care modalities, and service provi-
sion.29 Co-design techniques, such as the experience-based 
co-design (EBDC), involve collecting important experiences 
and data from patients and health care operators through 
qualitative techniques (such as in-depth interviews, observa-
tions, and focus groups), categorizing key points, so-called 
“touch points” (ie, areas with a relevant emotional impact) 
and allocating positive or negative feelings.30–32 The method 
was created to acquire knowledge and solutions that offer 
patients a better experience for dealing with cancer. It is an 
approach that enables health care operators and patients (and 
other service users) to co-design services for health care, 
together in partnership. Such collaboration may determine 
important practical consequences; for example, in the field 
of rehabilitation, it has been shown that the involvement of 
patients, who share experiences, everyday difficulties, and the 
way to process information, has resulted as a decisive factor 
in calibrating and modulating intervention for cognitive dis-
abilities.33,34 Similar results have been shown in the field of 
physical rehabilitation for chronic pain.35,36 Patients are pre-
cious resources whereby important research questions may 
be addressed and advances in treatment may be promoted. In 
addition, the advent of tailored medical treatments has brought 
about a greater need for supplementary scientific backing in 
order to evaluate the complex medical decision support data. 
In addition, the medical rationale needs to be communicated 
to the patient efficiently and effectively. Fortunately, clinical 
decision-making tools are making great strides. On the one 
hand, assessment tools may assist physicians in combining 
and examining large amounts of data (the results of laboratory 
exams, diagnostic tests, scientific literature, etc) and also in 
distributing such results among other health care operators. On 
the other hand, personalized tools may help physicians with 
data regarding the cognitive aspects of each patient, which 
will contribute to a more precise knowledge of expectations, 
fears, attitudes to risk, and health literacy. This should assist 
the physician in future interactions with the patient,  improving 
communication efficacy.37 The advent of telemedicine and 
 telecommunications is a further factor that allows patients and 
health providers to improve communication, exchange knowl-
edge, and create power21 both in the decision-making process 
and in disease and treatment management.  Furthermore, in 
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this regard, professionals cannot overlook the need to design 
such tools alongside and with the patient, who is after all, the 
final stakeholder.
Other important examples are related to the improvement 
of patient–doctor communication, especially in the field of 
clinical trials. It is well known that at an international level, 
the percentage of hypothetically qualified patients recruited 
to clinical trials is low, blocking the development of research 
evidence that may guide and enhance clinical practice.37,38 
The UK clinical research networks have been operating to 
increase quality, importance, and focus of research in their 
National Health Service (NHS), and initial outcomes in 
oncology have yielded evidence that the recruitment rate 
to cancer clinical trials has considerably increased.19 The 
majority of patients are quite interested in participating in 
randomized clinical trials (RCTs). Many of those initially 
refuse because of randomization; however, when the physi-
cian is able to explain the study in an accessible way and is 
able to take into account any possible fears and doubts, then 
the patients generally accept.39 These data demonstrate the 
relevance and need for clear communication and informa-
tion to support RCT participation. Evidence-based training 
courses should be available to help with this.
Cancer patient welfare is starting to become a key policy 
area, whereby governments are recognizing cancer patients 
as central to these plans.32 This is an ethical response to the 
plight of many of the patients in the community. It is also 
acknowledged that they have increasingly unique needs, and 
collaborative working and innovative thinking are called for 
on the part of health care professionals and politicians in 
order to see their needs met. However, much still remains 
to be done to bring care and involvement in-line with the 
rhetoric. It is unclear as to how involvement will be measured 
where there are no distinct plans and where the forthcoming 
financial climate over the next few years looms bleakly. As 
demonstrated, there is an undeniably strong ethical imperative 
to care for these patients, but it is one fraught with difficulties.
Disclosure
The authors report no conflicts of interest in this work.
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